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Abstract So far, the prognostic value of matrix metallopro-
teinase 2 (MMP-2) and tissue inhibitor of matrix metallopro-
teinase 2 (TIMP-2) expressions in patients with gliomas has
been widely reported, especially in China. But, the results
were inconsistent. Thus, we conducted a meta-analysis to de-
termine the correlation of MMP-2 and TIMP-2 expressions
with the prognosis of patients with gliomas. Identical search
strategies were used to search relevant literature in electronic
databases updated toMay 1, 2015, and odds ratios (ORs) with
95 % confidence intervals (95 % CIs) were estimated. Funnel
plots and Egger’s tests were conducted for the evaluation of
publication bias, and heterogeneity and sensitivity were also
analyzed. Finally, a total of 25 studies involving 1572 patients
were included in the meta-analysis. Coincidentally, all these
studies were conducted in Chinese population. It was found
that MMP-2 expression was significantly associated with
high-WHO grade gliomas (n=24, OR=6.54, CI=4.98–8.60;
I2=0 %, P=0.911) and poor overall survival (OS), while it
did not correlate to age (n=2, OR=0.78, CI=0.35–1.74; I2=
0 %, P=0.621) and gender (n=2, OR=1.15, CI=0.51–
2.62; I2=0 %, P=0.995). Moreover, the results of the pooled
analysis indicated that there was no association between
TIMP-2 expression and the WHO grade of gliomas (n=7,
OR=1.02, 95 % CI=0.68–1.54; I2=71.4 %, P=0.002), but
the ratio of MMP-2 and TIMP-2 (MMP-2/TIMP-2) rose with
the increase of the WHO grade of gliomas. In conclusion,
there was no correlation between TIMP-2 expression and the
WHO grade of gliomas, whileMMP-2 expression was potent-
ly associated with high-WHO grade of gliomas.
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Introduction
Gliomas are the most common primary central nervous system
tumor, whose treatment mainly comprises surgical resection,
postoperative radiotherapy, and chemotherapy [1, 2].
According to theWorldHealthOrganization, gliomas are divided
into four clinical grades (I–IV) based on the morphology of
histopathology [3]. While low-grade gliomas (I–II) are well dif-
ferentiated, high-grade gliomas (III–IV) are undifferentiated and
carry a worse prognosis [4, 5]. Thus, it is indispensable to iden-
tify precise biomarkers with predictive value for the grading of
gliomas and identification of the survival status of patients.
Matrix metalloproteinases (MMPs) are a family of en-
zymes which play a direct role in the tumorigenesis process
[6]. Type IV collagen is the main component of extracellular
matrix (ECM) and basement membrane which form the first
vital barrier in the course of tumor metastasis. Matrix metal-
loproteinase 2 (MMP-2), a main member of MMPs, by its
ability to degrade the basement membrane type IV collagen,
is thought to play a role in stromal and vascular invasion by
tumor cells [7, 8]. Van Meter et al. reported that tissue inhib-
itors of MMPs (TIMPs) can block the action of MMPs and
significantly decrease invasiveness of tumor [9]. And, TIMP-
2 which is a member of TIMPs has a unique dual function that
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being also an inhibitor of MMPs and with a more effective
action onMMP-2 [10]. The levels of bothMMP-2 and TIMP-
2 expressions in tumors may facilitate the initiation and pro-
gression of multiple biological behaviors required for tumor
progression [10]. It has been identified that the expression of
MMP-2 is associated with breast cancer [11], laryngeal cancer
[12], and gastric cancer [13]. And, the amounts of TIMP-2
expression have also been found to be associated with differ-
ent types of cancer [14, 15].
However, the results of studies on the association
between MMP-2 or TIMP-2 expression and brain tumors
were still contrary and there even existed conflicts. Some
studies reported that high TIMP-2 expression was associ-
ated with high-grade gliomas [16], but some studies gave
the contrary results [17], and others even showed that
TIMP-2 expression was not correlated with the WHO
grade of gliomas [18, 19]. Similarly, a number of studies
investigated the impact of MMP-2 expression on the prog-
nosis of patients with gliomas, but there were also no con-
sistent results. In order to evaluate the essential roles and




A literature search was carried out using PubMed, Ovid,
EMBASE, Web of Science, China National Knowledge
Infrastructure (CNKI), and Wanfang database updated to May 1,
2015. The search strategy used the following terms: (“metallopro-
teinase 2” or “MMP-2” or “type IV collagenase” or “gelatinase-
A”), (“ tissue inhibitor of metalloproteinase 2” or “TIMP-2”),
“gliomas [MeSH],” and “prognosis.” When the data reported in
the articles were not enough for the analysis, the authors of articles
were contacted. And, all references in retrieved articles were
scanned to identify other potentially available studies.
Inclusion and Exclusion Criteria
Two reviewers (GZ. Yi andWY. Feng) independently selected
eligible studies. Disagreements between the two reviewers
were settled by discussion with the third reviewer (Q. Zhou).
The inclusion criteria were as follows: (1) studies about
MMP-2 or TIMP-2 expression in patients with gliomas; (2)
case control or cohort studies; (3) the main outcome of studies
concentrated on WHO grade, age, gender, and overall surviv-
al; (4) MMP-2 and TIMP-2 expression which was measured
by immunohistochemistry (IHC); and (5) the hazard ratio
(HR) or odds ratio (OR) value which could be obtained from
the article directly.
Studies were excluded based on any of the following
criteria: (1) review, editorial letters, comments, or nonhuman
research and (2) lacked key information for HR or OR esti-
mation analysis. For duplicated articles, only the one with the
largest sample size or the most recent study was selected.
Data Extraction and Quality Assessment
The following information was gathered: the first author’s
name, year of publication, numbers of patients, mean age,
WHO grade, MMP-2 and TIMP-2 expression assay methods,
cutoff value of positive expression, and follow-up duration.
Relevant data were extracted by two reviewers (GZ. Yi and
WY. Feng) independently, and disagreement was resolved by
the third reviewer (Q. Zhou).
The quality assessment of the included studies was con-
ducted using the Newcastle-Ottawa Scale (NOS) with some
modifications [20] (Table 1), which allowed for assessment of
patient population and selection, comparability, and outcome.
Total NOS scores ranged from 0 to 9 with a score ≥6 indicat-
ing good quality [21].
Statistical Analysis
Quantitative meta-analysis was carried out using STATAversion
12.0. Dichotomous data were presented as relative risks (RRs) or
ORs, and continuous outcomes were presented as mean differ-
ence (MD), both with 95 % confidence interval (CI). Cochrane’s
Q test and I2 measurement were performed to assess the hetero-
geneity, and heterogeneity was presented as significant when I2≥
50 % or P≤0.10. In the absence of statistical heterogeneity, a
fixed-effect model was used to pool the results; otherwise, a
random-effect model was used [22]. The effects of MMP-2 or
TIMP-2 expression on pathological grade, age, and gender were
considered as statistically significant if the corresponding 95 %
CI for each pooledOR did not overlap 1, and an observedOR>1
indicated that gliomas of high-WHO grade were associated with
high MMP-2 or TIMP-2 expression.
The potential risk of publication bias was examined by
visual inspection of the funnel plots and was further assessed
by Egger’s linear regression test, which indicated the presence
of a publication bias with P≤0.10. Sensitivity analysis was




A total of 241 articles were identified by computer andmanual
search. After further reading, we excluded 216 studies accord-
ing to the eligibility criteria. Finally, 25 studies were included
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in the meta-analysis, of which 24 studies were related to
MMP-2 and gliomas and seven studies for TIMP-2 and
gliomas. The flowchart of the study selection for the meta-
analysis is shown in Fig. 1.
The major characteristics of all the included studies
are summarized in Table 2. Interestingly, all the includ-
ed studies were conducted in Chinese population, and
the date of publication ranged from 2002 to 2014.
Among all these studies, the correlation between the
ratio of MMP-2 and TIMP-2 (MMP-2/TIMP-2) and the
WHO grade of gliomas was offered in two studies [16,
39] and two studies [24, 27] provided the data of age
and gender which were associated with the WHO grade
of gliomas, and only one study [41] about MMP-2 ex-
pression reported the overall survival (OS) of patients.
MMP-2 and TIMP-2 expressions in the tissues of glio-
mas were only investigated by IHC method. If the nu-
cleus or cytoplasm was stained, the expression called
local staining can be referred to as positive. For the
cutoff value of positive expression, ten studies intro-
duced the scored method according to percentage and
intensity of stained cells, while the rest only used the
percentage or intensity.
MMP-2 Expression and Glioma Grade
A total of 24 studies involving 1453 patients contained suffi-
cient data for analyzing the association of MMP-2 expression
with different WHO grades of gliomas. It was found that
MMP-2 expression in patients with high-grade gliomas was
241 arcles retrieved by searching electronic 
databases
26 arcles were excluded for duplicaon
215 arcles were le for subsequent evaluaon
169 arcles were excluded due to:
(1) 87 arcles being non-human study;
(2) 61 arcles being abstracts, editorials, 
comments, or reviews;
(3) 21 arcles not relevant to MMP-2 or 
TIMP-2 and gliomas.
Full texts of 46 studies were reviews
21 studies were excluded due to:
(1) 8 studies reported the duplicated 
data;
(2) 7 studies with a quality score<6 were 
excluded;
(3) 6 studies had not enough data for 
analysis.
25 studies were included in the meta-analysis
Fig. 1 Flow chart of study selection
Table 1 Newcastle-Ottawa quality assessment scale
Selection
1. Representativeness of the exposed cohort
(a) Truly representative of the average glioma patients
in the community*
(b) Somewhat representative of the average glioma
patients in the community*
(c) Selected group of users (e.g., nurses, volunteers)
(d) No description of the derivation of the cohort
2. Selection of the non exposed cohort
(a) Drawn from the same community as the exposed cohort*
(b) drawn from a different source
(c) No description of the derivation of the nonexposed cohort
3. Ascertainment of exposure (proof of gliomas and MMP-2
or TIMP-2 measurement)




4. Demonstration that outcome of interest was not present




1. Comparability of cohorts on the basis of the
design or analysis
(a) Study controls for recurrence or metastasis*
(b) Study controls for any additional factor
(age, gender, grade, etc.)*
Outcome
1. Assessment of outcome




2. Was follow-up long enough for outcomes
to occur? (death or recurrence)
(a) Yes (24 months)*
(b) No
3. Adequacy of follow-up of cohorts
(a) Complete follow-up—all subjects accounted for*
(b) Subjects lost to follow-up unlikely to introduce
bias [small number lost (25 %) follow-up
or description provided of those lost]*
(c) Follow-up rate (<75 %) and no description of those lost
(d) No statement
A maximum of one star (*) can be given for each numbered item within
the “selection” and “outcome” categories, while a maximum of two stars
(**) can be given for “comparability”
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significantly higher than that in patients with low-grade glio-
mas (n=24, OR=6.54, CI=4.98–8.60), and there was no sig-
nificant heterogeneity in the meta-analysis (I2=0 %, P=
0.911) (Fig. 2). And, no correlation was observed between
MMP-2 expression and age (n=2, OR=0.78, CI=0.35–1.74;
I2=0 %, P=0.621) and also between MMP-2 and gender
(n=2, OR=1.15, CI=0.51–2.62; I2=0 %, P=0.995) through
a fixed-effect model (Fig. 3). The association of MMP-2 ex-
pression with overall survival (OS) was reported in one study
[41], and the results showed that highMMP-2 expression was
significantly associated with poor OS, while the exact data
were not reported.
TIMP-2 Expression and Glioma Grade
There were seven studies involving 463 patients on
TIMP-2 expression and the WHO grade of gliomas.
The results of pooled analysis demonstrated that there
was no significant association between TIMP-2 expres-
sion and tumor grade (n=7, OR=1.02, 95 % CI=0.68–
1.54) (Fig. 4a), but there was significant heterogeneity
(I2=71.4 %, P=0.002), so we performed the analysis
through a random-effect model. And, among these seven
studies involved, there were six studies that also report-
ed MMP-2 expression and glioma grade, so we also
conducted a meta-analysis to investigate the association
between MMP-2 expression and glioma grade among
these six studies. However, the overall trend was not
changed (n=6, OR=5.79, 95 % CI=3.36–9.98; I2=
0 %, P=0.982) (Fig. 4b).
MMP-2/TIMP-2 and Glioma Grade
Two studies reported the association between MMP-2/
TIMP-2 and the WHO grade of gliomas. Of which, one
study [16] used the percentage of positive cells after
Table 2 Characteristics of included studies
Study ID Sample size
(I–II/III–IV)










Sui R [23] 120 (70/50) 54.6 82/38 IHC Score=1 92 (46/46) NA 7/9 NA
Zeng ZQ [24] 64 (28/36) 38.8 38/26 IHC Score=2 43 (15/28) NA 6/9 NA
Guo GH [25] 40 (23/17) 45.9 26/14 IHC 5 % 24 (9/15) NA 6/9 NA
Wu HF [26] 45 (20/25) 42.3 31/14 IHC 10 % 21 (5/16) NA 6/9 NA
Pan LK [27] 50 (24/26) 46.3 32/18 IHC 10 % 37 (14/23) NA 6/9 NA
Li B [18] 52 (32/20) 47.6 34/18 IHC 10 % 22 (9/13) 23 (15/8) 6/9 NA
Jv HG [16] 78 (43/35) 42.4 48/30 IHC Score=1 50 (21/29) 46 (21/25) 6/9 NA
Liu Q [28] 60 (27/33) 40.2 32/28 IHC Score=2 49 (19/30) NA 7/9 NA
Sun SW [19] 45 (20/25) 40.2 24/21 IHC Score=2 36 (13/23) 24 (9/15) 6/9 NA
Zhao YF [29] 50 (17/33) 40.0 28/22 IHC 10 % 34 (8/26) NA 6/9 NA
Song LJ [30] 100 (47/53) 42.3 58/42 IHC Score=1 76 (24/52) NA 6/9 NA
Kong LF [31] 135 (64/71) 34.8 76/59 IHC 5 % 49 (11/38) NA 6/9 NA
Lv ZH [32] 30 (12/18) 41.3 12/18 IHC 10 % 17 (3/14) NA 6/9 NA
Zhou R [17] 67 (27/40) 43.1 40/27 IHC 10 % 41 (10/31) 41 (22/19) 6/9 NA
Li Hao [33] 50 (23/27) 48.7 28/22 IHC Local staining 39 (13/26) NA 6/9 NA
Li Hong [34] 119 (55/64) 42.0 66/53 IHC Score=1 NA 106 (45/61) 7/9 NA
Wang YT [35] 45 (20/25) 40.2 21/22 IHC Score=1 36 (13/23) NA 6/9 NA
Liu ZL [36] 50 (16/34) 40.4 27/23 IHC Score=1 46 (13/33) NA 6/9 NA
Tan YL [37] 68 (33/35) 38.1 37/31 IHC Score=1 49 (16/33) NA 7/9 NA
Shi QH [38] 46 (21/25) 42.5 26/20 IHC Local staining 28 (8/20) NA 6/9 NA
Yi ZQ [39] 46 (22/24) 38.5 26/20 IHC 5 % 37 (14/23) 17 (8/9) 7/9 NA
Li J [40] 46 (30/16) 38.5 30/16 IHC 5 % 20 (7/13) NA 6/9 NA
Xiao QH [41] 60 (20/40) 35.0 42/18 IHC 5 % 15 (1/14) NA 8/9 >24 M
Luo GC [42]
Fu XW
56 (25/31) 34.8 33/23 IHC 5 % 47 (18/29) 42 (22/20) 6/9 NA
[43] 50 (25/25) 48.5 27/23 IHC 25 % 22 (8/14) NA 6/9 NA
Tumor grade was described on the basis of the World Health Organization (WHO) grading system of primary brain tumors and divided into two groups:
low grade (I–II) and high grade (III–IV)
IHC immunohistochemistry, NA not available
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IHC to calculate the ratio, and the results showed that
with the increase of tumor grade, MMP-2/TIMP-2 rose
from 1.00 to 1.18. The other study [39] detected the
gray value of microscopic field (10×40) and calculated
the ratio, which the reported ratio is (0.83±0.046) for
low-grade gliomas and (0.46±0.094) for high-grade tu-
mor, while a high gray value represented the lower per-
centage of positive cells.
Publication Bias and Sensitivity Analysis
Visual inspection of the funnel plot revealed asymmetry in
analysis of the association between MMP-2 or TIMP-2 ex-
pression and glioma grade, indicating the possibility of publi-
cation bias (Fig. 5a, b). We also estimated the publication bias
through using Egger’s linear regression test. The results re-
vealed support for significant publication bias in MMP-2
group (t=3.90, P=0.001) while did not reveal any publication
bias among studies on TIMP-2 expression and glioma grade
(t=−0.69, P=0.521).
Sensitivity analyses were also conducted to ascertain the
effects attributable to any individual study, while the results
showed that no individual study could change the overall
trends. It suggested that the results of the meta-analysis were
stable (Fig. 5c, d).
Discussion
Gliomas are the most common type of primary cerebral tu-
mors. According to the WHO, gliomas can be divided into
four clinical grades [3]. However, the molecular func-
tions in glioma grade are still not wholly understood,
and the prognoses of patients with gliomas remain dis-
mal [44]. It is important for us to find the molecular
markers for the progression and prognosis of gliomas,
which would be of great benefit in selecting the
Fig. 2 Forest plot of association between MMP-2 expression and the WHO grade of gliomas
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therapeutic strategies and improving patients’ survival. Many
studies have shown that MMP-2 and TIMP-2 play crucial
roles in various human cancers, including gliomas. But, all
the results of these studies about gliomas remained controver-
sial, so it is necessary to perform a meta-analysis.
In our meta-analysis, the results of 24 studies involving
1453 patients demonstrated that the expression of MMP-2 in
patients with high-grade gliomas increased significantly as
compared to patients with low-grade gliomas, while no corre-
lation was observed between MMP-2 and age, and also no
association was found between MMP-2 and gender. There
were also evidences that high MMP-2 expression was associ-
ated with poor OS in patients with gliomas. Moreover, our
meta-analysis determined that there was no association be-
tween TIMP-2 expression and the WHO grade of gliomas,
and the overall trend of MMP-2 expression and glioma grade
was not changed in studies which have reported both MMP-2
and TIMP-2 expressions. And, MMP-2/TIMP-2 rose with the
increase of glioma grade, which may be used as criteria of
WHO grade in gliomas.
Fig. 3 Forest plot of association between MMP-2 expression and gender, age
Fig. 4 Forest plot of association between TIMP-2 expression and the WHO grade of gliomas (a) and association between MMP-2 expression and
glioma grade in studies which have also reported TIMP-2 expression (b)
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Both funnel plots and Egger’s tests indicated that publica-
tion biases were present in the analysis of association of
MMP-2 expressions with glioma grade, though we performed
a quality assessment of studies to avoid some selection biases
and attempted to minimize publication bias by performing the
literature search as complete as possible. However, our search
was restricted to studies published in English or
Chinese, and the studies with negative results were of-
ten rejected [45]. So, publication bias may be a limita-
tion in our meta-analysis.
Despite our efforts to conduct a comprehensive analysis,
there were also some other limitations which should be
discussed. Firstly, the heterogeneity among studies about
TIMP-2 expression and glioma grade may affect the results
of the present meta-analysis. Secondly, all the MMP-2 and
TIMP-2 expressions weremeasured by IHC and all the studies
were conducted in Chinese population. IHC was the most
frequently applied method, but methodological differences
may contribute to the heterogeneity. And, subgroup analysis
could not be conducted to address these technical problems
because few studies offered the concrete data. Thirdly, there
was no consistent threshold value to define positive expres-
sion in assessment ofMMP-2 and TIMP-2 expressions, which
can be the cause of potential bias. Lastly, there was only one
study that reported the data about MMP-2 expression and the
OS and only two studies analyzed the association between
MMP-2/TIMP-2 and the grade of gliomas. Due to the limited
number of studies included, the findings about the impact of
Fig. 5 Funnel plots and sensitivity analysis of the meta-analysis. Funnel
plots of the meta-analysis assessing a MMP-2 expression and glioma
grade and b TIMP-2 expression and glioma grade and sensitivity
analysis of the meta-analysis assessing c MMP-2 expression and glioma
grade and d TIMP-2 expression and glioma grade
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MMP-2 expression or MMP-2/TIMP-2 on the prognosis of
gliomas should be interpreted with caution.
Considering all these limitations existing in this meta-anal-
ysis, the conclusions of this meta-analysis should be drawn
carefully. In summary, our meta-analysis concluded that high
MMP-2 expression was associated with high-grade gliomas,
and there was no correlation between TIMP-2 expression and
the WHO grade of gliomas. MMP-2/TIMP-2 testing may pre-
dict the WHO grade of gliomas, and MMP-2 expression may
serve as a biomarker for the prognosis of patients with glio-
mas, which required to be further certified by future studies.
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